https://pepsreview.com/articles/fda-coordinated-enforcement-sweep-targets-peptide-sellers PepsReview en 2026-09-13 FDA enforcement, peptide sellers, FDA sweep, unapproved peptides, peptide regulation, GLP-1 enforcement, peptide import screening https://pepsreview.com/articles/verification-tools-proliferate-as-peptide-buyers-demand-proof PepsReview en 2026-09-13 peptide claims verification, evidence checker, peptide purity testing, COA verification, research peptide market, peptide quality control, third party testing https://pepsreview.com/articles/market-intelligence-index-tracks-100-peptide-vendors-112000-public-coa-records PepsReview en 2026-09-13 peptide market intelligence, peptide vendor comparison, COA records, peptide prices, research peptide market, peptide testing, vendor transparency https://pepsreview.com/articles/oral-glp-1-prescriptions-keep-climbing-tablets-find-their-place PepsReview en 2026-09-12 oral GLP-1, Wegovy pill, orforglipron, oral semaglutide, GLP-1 prescriptions, weight loss tablet, peptide testing, counterfeit peptides https://pepsreview.com/articles/glp-1-weight-loss-market-under-fire-big-promises-regulatory-reality PepsReview en 2026-09-12 GLP-1 market, weight loss marketing, compounded semaglutide, compounded tirzepatide, FDA enforcement, peptide purity, telehealth weight loss https://pepsreview.com/articles/fda-approves-eli-lilly-oral-glp-1-weight-loss-pill PepsReview en 2026-09-12 orforglipron, Eli Lilly, FDA approval, oral GLP-1, weight loss pill, obesity medication, GLP-1 news https://pepsreview.com/articles/semaglutide-shortage-ends-window-closes-for-compounded-copies PepsReview en 2026-09-12 semaglutide shortage, compounded semaglutide, FDA shortage list, compounding pharmacies, 503B, GLP-1 supply, enforcement https://pepsreview.com/articles/retatrutide-remains-investigational-2026-phase-3-triumph-readouts PepsReview en 2026-09-12 retatrutide, retatrutide FDA status, TRIUMPH phase 3, triple agonist peptide, Eli Lilly obesity drug, gray market peptides, investigational peptide, GLP-1 research https://pepsreview.com/articles/independent-peptide-testing-capacity-expands-purity-concerns PepsReview en 2026-09-12 peptide testing, HPLC purity testing, LC-MS analysis, certificate of analysis, independent lab testing, research peptide purity, third party verification https://pepsreview.com/articles/glp-1-prescriptions-surge-young-children-pediatric-obesity-trials PepsReview en 2026-09-11 GLP-1 children, pediatric obesity, semaglutide kids, Wegovy children, off-label GLP-1, obesity drugs, Novo Nordisk, Eli Lilly https://pepsreview.com/articles/wegovy-china-approval-first-glp-1-mash-liver-disease PepsReview en 2026-09-11 Wegovy China approval, MASH, semaglutide liver disease, GLP-1 hepatology, fatty liver, Novo Nordisk, NMPA, metabolic liver disease https://pepsreview.com/articles/glp-1-vision-loss-lawsuits-eli-lilly-zepbound-trulicity PepsReview en 2026-09-11 Zepbound lawsuit, Trulicity vision loss, NAION, Eli Lilly litigation, GLP-1 blindness, tirzepatide side effects, drug lawsuits, semaglutide NAION https://pepsreview.com/articles/moonwalk-raises-70m-fat-targeting-rnai-obesity-clinic PepsReview en 2026-09-11 Moonwalk funding, RNAi obesity, fat-targeting RNAi, obesity pipeline, obesity drug development, gene silencing, biotech funding, GLP-1 alternatives https://pepsreview.com/articles/novo-nordisk-il-6-inhibitor-flunks-two-more-heart-trials PepsReview en 2026-09-11 Novo Nordisk IL-6 inhibitor, cardiovascular outcomes trial, inflammation cardiology, ziltivekimab, heart trial failure, chronic kidney disease, drug trials, GLP-1 diversification https://pepsreview.com/articles/mhra-freezes-bank-accounts-illegal-weight-loss-jab-probe PepsReview en 2026-09-11 MHRA, weight-loss jab investigation, Operation Dunlin, retatrutide seizure, peptide enforcement, GLP-1 safety, counterfeit injectables https://pepsreview.com/articles/compounded-semaglutide-tirzepatide-1700-federal-problem-reports PepsReview en 2026-09-11 compounded semaglutide, compounded tirzepatide, FDA adverse events, GLP-1 problem reports, peptide quality, 503B bulks list, telehealth warning letters https://pepsreview.com/articles/pretoria-court-blocks-appeal-semaglutide-compounding-fight PepsReview en 2026-09-11 semaglutide compounding, Novo Nordisk lawsuit, South Africa pharmacy court, Pretoria High Court, GLP-1 enforcement, compounded GLP-1 ban https://pepsreview.com/articles/researchers-peptide-evidence-just-not-there PepsReview en 2026-09-11 peptide evidence, unapproved peptides, clinical research, peptide safety, GLP-1 evidence, medicine safety, peptide claims https://pepsreview.com/articles/doctors-warn-peptide-safety-concerns-use-surges PepsReview en 2026-09-11 peptide safety, doctors warning, self-medication risks, unverified peptides, peptide testing, adverse events, research peptides